Calcium channel blockers: Is the jury still out?

doi:10.1136/bmj.317.7172.1591

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

James M Wright, Associate professor

Departments of Pharmacology, Therapeutics, and Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

EDITOR—Stanton's editorial on calcium channel blockers1 is based on an incomplete review of the available evidence. I found three additional published randomised controlled trials in which calcium channel blockers were compared with other drugs for the treatment of hypertension in predominantly non-diabetic patients.2^–4 The study group on long term antihypertensive therapy2 compared an angiotensin converting enzyme inhibitor, …